NASDAQ : BPMC

Blueprint Medicines Corporation

$129.46 USD

$0.18 (0.14%)

Volume
2.98M
Average Volume
3.29M
Market Capitalization
$8.36B
P/E Ratio
-120.99
Dividend Yield
0.00%
Price Target
$120.00
Year High
$129.55
Year Low
$73.04
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.85
Company Overview

NASDAQ

Kathryn Haviland

Biotechnology

Healthcare

BPMC

682

US

USD

https://www.blueprintmedicines.com

617 374 7580

09627Y109

0001597264

Liquidity Metrics

1.57

2.85

2.80

0.39

0.00

Sales & Valuation

$508.82M

16.43

27.25

-42.39

-3.14

Profitability

-$1.07

-$67.09M

-13.19%

-12.94%

-31.26%

-5.69%

P/E Metrics

-120.99

0.58

0.58

Analyst Price Target & Rating

$120.00

$155.00

$41.00

N/A

0/5

34 Analysts

7.88%

Poll Results

About Blueprint Medicines Corporation (NASDAQ:BPMC) Stock

Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRET ... O is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.

Frequently Asked Questions

What is the current Blueprint Medicines Corporation (BPMC) stock price?

Blueprint Medicines Corporation(NASDAQ:BPMC) stock price is $129.46 in the last trading session. During the trading session, BPMC stock reached the peak price of $129.55 while $73.04 was the lowest point it dropped to. The percentage change in BPMC stock occurred in the recent session was 0.14% while the dollar amount for the price change in BPMC stock was $0.18.

BPMC's industry and sector of operation?

The NASDAQ listed BPMC is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BPMC?

Michael Landsittel | Chief Financial Officer
Christina Rossi | Chief Operating Officer
Kathryn Haviland | President, Chief Executive Officer & Director
Becker Hewes | Chief Medical Officer
Alexis A. Borisy | Co-Founder & Director

How many employees does BPMC have?

Number of BPMC employees currently stands at 682. BPMC operates from 45 Sidney Street, Cambridge, MA 02139, US.

Link for BPMC official website?

Official Website of BPMC is: https://www.blueprintmedicines.com

How do I contact BPMC?

BPMC could be contacted at phone #617 374 7580 and can also be accessed through its website. BPMC operates from 45 Sidney Street, Cambridge, MA 02139, US.

How many shares of BPMC are traded daily?

The average number of BPMC shares traded daily for last 3 months was 3.29M.

What is the market cap of BPMC currently?

The market value of BPMC currently stands at $8.36B with its latest stock price at $129.46